Bevonescein (ALM 488) Infusion for head and neck neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 8 Jun 2026: Trial registered, NCT07631650
  2. 4 Nov 2026: Trial started, NCT07631650

The trials

NCT07631650: Bevonescein for Improved Intraoperative Nerve Visualization to Improve Voice Outcomes in Thyroidectomy Patients

State
Under way
Phase
Phase 2
People
40 planned
Started
4 Nov 2026
Primary completion
4 Nov 2027
Arms
Bevonescein (ALM 488) Infusion
Results
None posted
  1. 8 Jun 2026: Trial registered
  2. 4 Nov 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.